As shown in Fig. 2A, in TCGA, high expression of DYRK2 predicted poorer overall survival in KICH (Kidney Chromophobe) (P = 0.0083), LAML (Acute Myeloid Leukemia) (P = 0.039), UVM (Uveal Melanoma) (P = 0.039), MESO (Mesothelioma) (P = 0.026) and ESCA(Esophageal carcinoma) (P = 0.048). Here, DYRK2 is linked to uveal melanoma.